---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-057155"
form_type: "8-K"
ticker: "GALT"
cik: "0001133416"
company_name: "GALECTIN THERAPEUTICS INC"
filed_at: "2023-12-11T23:59:59+00:00"
generated_at: "2026-06-07T14:42:03.573658+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Galectin Therapeutics announces 2023 annual meeting results; all director nominees elected

## Summary
- All 11 director nominees elected; highest vote total for Kary Eldred at 25,603,577 for.
- Ratification of Cherry Bekaert LLP as auditor approved: 44,481,830 for, 252,254 against.
- Amendment to 2019 Omnibus Equity Incentive Plan to add 3,000,000 shares approved: 23,901,293 for, 1,923,578 against, 18,910,166 broker non-votes.

## SEC filing metadata
- accession: 0001140361-23-057155
- form_type: 8-K
- ticker: GALT
- cik: 0001133416
- company_name: GALECTIN THERAPEUTICS INC
- filed_at: 2023-12-11T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1133416/000114036123057155/0001140361-23-057155-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1133416/000114036123057155/ef20016443_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-057155
- JSON: https://secwatch.observer/filing/0001140361-23-057155.json
- Plain text: https://secwatch.observer/filing/0001140361-23-057155.txt

## Key facts
- Shareholder Votes
  GALECTIN THERAPEUTICS INC shareholders approved Ratification of the selection of Cherry Bekaert LLP as the independent registered public accounting firm for the Company for the year ending December 31, 2023 at the 2023-12-07 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-12-07
  source text: Ratification of the selection of Cherry Bekaert LLP as the independent registered public accounting firm for the Company for the year ending December 31, 2023 Votes For Votes Against Votes Abstain 44,481,830 252,254 187,704
  evidence_url: https://www.sec.gov/Archives/edgar/data/1133416/000114036123057155/0001140361-23-057155-index.htm
- Shareholder Votes
  GALECTIN THERAPEUTICS INC shareholders approved Election of Directors at the 2023-12-07 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-12-07
  source text: Election of Directors Name Votes For Votes Withheld Broker Non-Votes Gilbert F. Amelio, Ph.D. 24,856,340 1,155,282 18,910,166
  evidence_url: https://www.sec.gov/Archives/edgar/data/1133416/000114036123057155/0001140361-23-057155-index.htm
- Shareholder Votes
  GALECTIN THERAPEUTICS INC shareholders approved Approved an amendment to our 2019 Omnibus Equity Incentive Plan to reserve an additional 3,000,000 shares for issuance under the plan at the 2023-12-07 meeting.
  - Proposal: equity plan
  - Outcome: passed
  - Meeting: 2023-12-07
  source text: Approved an amendment to our 2019 Omnibus Equity Incentive Plan to reserve an additional 3,000,000 shares for issuance under the plan. Votes For Votes Against Votes Abstain Broker Non-Votes 23,901,293 1,923,578 186,751 18,910,166
  evidence_url: https://www.sec.gov/Archives/edgar/data/1133416/000114036123057155/0001140361-23-057155-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.